M. Itoh, T. Suganami, N. Satoh, et al., “Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 9, 2007, pp. 1918-1925.doi10.1161/ATVBAHA.106.136853 - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

M. Itoh, T. Suganami, N. Satoh, et al., “Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 9, 2007, pp. 1918-1925. doi:10.1161/ATVBAHA.106.136853

has been cited by the following article:

TITLE: Can Purified Omega-3 Polyunsaturated Fatty Acids Supplementation Act Blood Pressure Levels in Untreated Normal-High Blood Pressure Subjects with Hypertriglyceridemia?

AUTHORS: Maria Leonarda De Rosa

KEYWORDS: Omega-3PUFAs; Blood Pressure; Hypertriglyceridemia

JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.2, April 25, 2012

ABSTRACT: Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but significant decrease in blood pressure (BP) level. In fact, omega-3 PUFAs exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion, partly competing with omega-6 PUFAs for common metabolic enzymes and thereby decreasing the production of vasoconstrictor rather than vasodilator and anti-inflammatory eicosanoids. PUFAs also reduce angiotensin-converting enzyme (ACE) activity, angiotensin II formation. We retrospectively evaluated the long-term effect of a omega-3 PUFAs supplementation on the blood pressure level of 91 hypertriglyceridemic subjects with untreated normal-high blood pressure that were prescribed a 3 grams omega-3 PUFAs supplementation in order to improve their plasma lipid pattern. After 24 months of treatment, systolic blood pressure (SBP) meanly decreased by 2.6 +/- 2.5 mmHg (p = 0.001) and diastolic blood pressure (DBP) by 1.4 +/- 3.1 mmHg (p